Skip to content
akaturk Academic measurement

Article detail · 2019

Investigating the cytotoxic and apoptotic effects of sunitinib upon K-562 chronic myelogenous leukemia cell line and assessment of gene profiling

YÖKSİS OpenAlex Open access · diamond SJR Q2 JCR Q4 Citations 3 Percentile 46.1% FWCI 0.14
Year
2019
Type
article

Data source split

  • YÖKSİS YÖKSİS article record
  • YÖKSİS venue Journal of Cancer Research and Therapeutics
  • Catalog match (ISSN) Journal of Cancer Research and Therapeutics
  • OpenAlex OpenAlex enrichment (abstract, citations, topics)

Abstract

English (OpenAlex)

OBJECTIVE: Tyrosine kinase inhibitors (TKIs) which efficiently inhibit BCR-ABL are highly effective for clinical treatment of chronic myeloid leukemia (CML), but development of resistance to TKIs is a big challenge to treatment. Sunitinib is a multitargeted TKI targeting vascular endothelial growth factor receptor and is defined a safe and effective candidate target, but its effect on other signaling pathways is unknown. To investigate the cytotoxic and apoptotic effect of sunitinib in CML cell model K-562 on JAK-STAT signaling pathway components, suppressor genes and oncogenes, hematopoiesis-related genes, cell cycle and VEGF pathway components, and mRNA level expression changes was aimed. MATERIALS AND METHODS: was determined by trypan blue and WST-1 cell proliferation assay tests. Expression levels of target genes were determined by quantitative reverse transcriptase polymerase chain reaction simultaneously after sunitinib application. Protein expression analysis was determined by "WesternBreeze Chromogenic Kit-Anti-Rabbit" based on the principles of the application kit by Western blot analysis. RESULTS: h for K-562 cells and apoptosis assays pointed that sunitinib induces apoptotic cell death of leukemic cells at moderate levels. CONCLUSION: Our study supports that sunitinib might be used as a novel therapeutic target to trigger apoptosis in CML cells which in turn might accelerate therapeutic response in regard to inhibiting oncogenes and enhancing tumor suppressors in cooperation with cell cycle regulatory genes.

Topics

  • Chronic Myeloid Leukemia Treatments
  • Cytokine Signaling Pathways and Interactions
  • Myeloproliferative Neoplasms: Diagnosis and Treatment

Primary topic Chronic Myeloid Leukemia Treatments

Authors

  1. MELDA CÖMERT
  2. BURÇİN KAYMAZ EGE ÜNİVERSİTESİ
  3. AJDA GÜNEŞ EGE ÜNİVERSİTESİ
  4. BUKET KOSOVA EGE ÜNİVERSİTESİ
  5. NUR SOYER EGE ÜNİVERSİTESİ
  6. ASU FERGÜN YILMAZ
  7. FİLİZ VURAL
  8. FAHRİ ŞAHİN EGE ÜNİVERSİTESİ
  9. GÜRAY SAYDAM EGE ÜNİVERSİTESİ